Simplified radial artery haemostasis: using non-compressive dressings—the Radial Artery Puncture Haemostasis Evaluation trial: results of the RAPHE trial

1. Hemostasis Efficacy

• 96% of patients achieved successful hemostasis with Axiostat®
• 95% achieved hemostasis at the first checkpoint (10 minutes of compression)
• Demonstrated efficacy in patients receiving up to 10,000 IU heparin
• Proven effective in patients on antiplatelet and anticoagulant therapies (including aspirin, clopidogrel, prasugrel, ticagrelor, apixaban)
• Effective across multiple sheath sizes (5F, 6F, 7F)

2. Clinically Proven Safety — Radial Artery Preservation

• 100% arterial patency confirmed post-application (via pulse oximetry)
• Zero cases of radial artery dissection reported
• No device-related allergic reactions or adverse events observed
• 98.5% of patients free from major haematoma
• 98.5% with no clinically significant complications (pseudoaneurysm or arteriovenous fistula)
• 97% of patients showed no radial artery occlusion (RAO)
• Intact radial artery observed in 97.5% of patients

3. Operational Benefits at Cath lab Simplified Workflow & Reduced Staff Burden

• Eliminates the need for continuous patent haemostasis monitoring required with manual compression devices (MCD)
• Significantly reduces post-procedure nursing interventions
• Frees up clinical staff for higher-priority tasks, improving overall cath lab efficiency

4. Simplified Protocol

• Avoids repeated adjustments typically required every 10–15 minutes with MCD
• Requires minimal observation following application
• Application time shorter (3 minute less) compared to conventional MCD

5. Improved Patient Experience

• Easy and atraumatic removal (saline irrigation; no painful peel-off)
• Shorter overall device management time with Axiostat supports earlier patient mobilisation and same-day discharge protocols.